In this study, we show that sorafenib sensitizes Apo2L/TRAIL-resistant cancer cells and enhances cell death in Apo2L/TRAIL-sensitive solid tumors in combination with mapatumumab, lexatumumab, or Apo2L/TRAIL. Here, TNFSF10 is linked to cancer.